PMI Steering Committee member Prof. Robert Huber was elected Fellow of the Optical Society of America (OSA).
Professor Robert Huber, Director of the Institute for Biomedical Optics at the University of Lübeck, has been elected as a fellow of the Optical Society of America (OSA). He receives this distinction “for outstanding contributions to the development of tunable lasers and imaging techniques, especially Fourier domain mode locking”.
Since 1959, over 2,500 members have joined the ranks of OSA Fellow. These members have served with distinction in the advancement of optics and photonics through distinguished contributions to education, research, engineering, business and society. The number of elected Fellows is limited by the Society's bylaws to be no more than 10% of the total OSA Membership and the number each year is limited to approximately 0.5% of the current membership total.
Professor Dr. Robert Huber
Institute for Biomedical Optics
+49 451 31013202
About the Cluster of Excellence PMI
The Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI) is being funded from 2019 to 2025 through the German Excellence Strategy (ExStra). It succeeds the "Inflammation at Interfaces” Cluster, which was already funded in two periods of the Excellence Initiative (2007-2018). Around 300 members from eight institutions at four locations are involved: Kiel (Kiel University, University Medical Center Schleswig-Holstein (UKSH), Muthesius University of Fine Arts and Design, Kiel Institute for the World Economy (IfW), Leibniz Institute for Science and Mathematics Education (IPN)), Lübeck (University of Lübeck, University Medical Center Schleswig-Holstein (UKSH)), Plön (Max Planck Institute for Evolutionary Biology) and Borstel (Research Center Borstel - Leibniz Lung Center).
The goal is to translate interdisciplinary research findings on chronic inflammatory diseases of barrier organs to healthcare more intensively, as well as to fulfil previously unsatisfied needs of the patients. Three points are important in the context of successful treatment, and are therefore at the heart of PMI research: the early detection of chronic inflammatory diseases, the prediction of disease progression and complications, and the prediction of individual responses to treatment.